再発性多形性膠芽腫(Recurrent Glioblastoma Multiforme (GBM)):治療薬開発パイプライン動向(2015年上半期版)...市場調査レポートについてご紹介

【英文タイトル】Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Recurrent Glioblastoma Multiforme (GBM) Overview 8
Therapeutics Development 9
Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) – Overview 9
Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) – Comparative Analysis 10
Recurrent Glioblastoma Multiforme (GBM) – Therapeutics under Development by Companies 11
Recurrent Glioblastoma Multiforme (GBM) – Therapeutics under Investigation by Universities/Institutes 15
Recurrent Glioblastoma Multiforme (GBM) – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Recurrent Glioblastoma Multiforme (GBM) – Products under Development by Companies 19
Recurrent Glioblastoma Multiforme (GBM) – Products under Investigation by Universities/Institutes 22
Recurrent Glioblastoma Multiforme (GBM) – Companies Involved in Therapeutics Development 23
Agenus, Inc. 23
Amgen Inc. 24
AngioChem Inc. 25
Apogenix GmbH 26
AstraZeneca PLC 27
Axelar AB 28
Boehringer Ingelheim GmbH 29
Boston Biomedical, Inc. 30
Celldex Therapeutics, Inc. 31
e-Therapeutics plc 32
Eisai Co., Ltd. 33
Eli Lilly and Company 34
EnGeneIC Ltd 35
ERC Belgium SA 36
GenSpera, Inc. 37
GlaxoSmithKline plc 38
GW Pharmaceuticals plc 39
ImmunoCellular Therapeutics, Ltd. 40
Karyopharm Therapeutics, Inc. 41
Merck & Co., Inc. 42
Novartis AG 43
OncoEthix SA 44
Ono Pharmaceutical Co., Ltd. 45
Pfizer Inc. 46
Sangamo BioSciences, Inc. 47
Spectrum Pharmaceuticals, Inc. 48
Threshold Pharmaceuticals, Inc. 49
Tocagen Inc. 50
Vascular Biogenics Ltd. 51
Virttu Biologics Limited 52
ZIOPHARM Oncology, Inc. 53
Recurrent Glioblastoma Multiforme (GBM) – Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Combination Products 55
Assessment by Target 56
Assessment by Mechanism of Action 60
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 67
(GWP-42002 + GWP-42003) – Drug Profile 67
Ad-RTS-IL-12 – Drug Profile 68
afatinib – Drug Profile 70
AMG-595 – Drug Profile 74
ANG-1005 – Drug Profile 76
APG-101 – Drug Profile 78
axitinib – Drug Profile 80
AXL-1717 – Drug Profile 83
AZD-7451 – Drug Profile 85
BBI-608 – Drug Profile 86
BGJ-398 – Drug Profile 89
bosutinib – Drug Profile 90
buparlisib hydrochloride – Drug Profile 92
capmatinib – Drug Profile 96
dacomitinib – Drug Profile 98
Dendritic Cell Therapy for Recurrent Glioblastoma Multiforme – Drug Profile 100
DNX-2401 – Drug Profile 101
doxorubicin – Drug Profile 103
ERC-1671 – Drug Profile 104
erismodegib – Drug Profile 106
ETS-2101 – Drug Profile 109
evofosfamide – Drug Profile 111
G-200 – Drug Profile 118
galunisertib – Drug Profile 120
golvatinib + lenvatinib – Drug Profile 122
HSV-1716 – Drug Profile 124
ICT-121 – Drug Profile 127
lonafarnib – Drug Profile 128
MDNA-55 – Drug Profile 130
mipsagargin – Drug Profile 131
nabiximols – Drug Profile 133
nivolumab – Drug Profile 136
Oncolytic Virus for Oncology – Drug Profile 142
Oncolytic Virus to Target IL-12 for Oncology – Drug Profile 143
ortataxel – Drug Profile 144
OS-2966 – Drug Profile 145
OTX-015 – Drug Profile 146
pazopanib hydrochloride – Drug Profile 148
pembrolizumab – Drug Profile 153
ribociclib – Drug Profile 158
rilotumumab – Drug Profile 161
rindopepimut – Drug Profile 163
SB-313 – Drug Profile 165
selinexor – Drug Profile 166
SGT-53 – Drug Profile 170
TPI-287 – Drug Profile 172
trebananib – Drug Profile 174
Vaccine to Target Carcinoembryonic Antigen for Oncology – Drug Profile 177
vandetanib – Drug Profile 178
VB-111 – Drug Profile 184
vocimagene amiretrorepvec + flucytosine ER – Drug Profile 185
Recurrent Glioblastoma Multiforme (GBM) – Recent Pipeline Updates 187
Recurrent Glioblastoma Multiforme (GBM) – Dormant Projects 274
Recurrent Glioblastoma Multiforme (GBM) – Discontinued Products 275
Recurrent Glioblastoma Multiforme (GBM) – Product Development Milestones 276
Featured News & Press Releases 276
Appendix 283
Methodology 283
Coverage 283
Secondary Research 283
Primary Research 283
Expert Panel Validation 283
Contact Us 283
Disclaimer 284


【レポート販売概要】

■ タイトル:再発性多形性膠芽腫(Recurrent Glioblastoma Multiforme (GBM)):治療薬開発パイプライン動向(2015年上半期版)
■ 英文:Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015
■ 発行日:2015年3月11日
■ 調査会社:Global Markets Direct
■ 商品コード:GMDHC6256IDB
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。